Differentially expressed epitopes and uses thereof
First Claim
1. A process for identifying a disease associated molecular marker which disease associated molecular marker is associated with a subset of cells, said process comprising the steps of:
- a) incubating cells of a species with a library of binding molecules, combined with an incubation with diseased cells of the species;
b) obtaining, from said incubation, a collection of diseased cells essentially free from non-diseased cells, by sorting said collection of diseased cells from non-diseased cells according to parameters that distinguish between said collection of diseased cells and said non-diseased cells;
c) obtaining binding molecules from said collection of diseased cells;
d) selecting, from said obtained binding molecules, an individual binding molecule that preferentially binds to said diseased cells in comparison to binding to said non-diseased cells;
e) identifying a molecular marker which, in its disease associated form, binds to said individual binding molecule selected under step d), said disease associated molecular marker being associated with said collection of diseased cells obtainable according to step b); and
f) establishing that said disease associated molecular marker has a counterpart associated with non-diseased cells wherein said counterpart is less capable of binding said individual binding molecule.
1 Assignment
0 Petitions
Accused Products
Abstract
Provided are, among other things, novel epitopes, methods for finding these epitopes and binding molecules capable of binding to said novel epitopes. In one aspect, the invention provides a binding molecule capable of specifically binding to a preferably, post-translationally modified, disease associated molecular marker, associated with diseased cells, whereas the preferably post-translationally modified disease associated molecular marker is not associated with non-diseased cells. In a preferred aspect of the invention, the binding molecule recognizes an epitope present in a subset of CD46 proteins. The binding molecule is capable of distinguishing between CD46 proteins belonging to the subset and CD46 proteins not belonging to the subset. The binding molecule is preferably an antibody. Medicaments and uses of binding molecules are provided.
47 Citations
49 Claims
-
1. A process for identifying a disease associated molecular marker which disease associated molecular marker is associated with a subset of cells, said process comprising the steps of:
-
a) incubating cells of a species with a library of binding molecules, combined with an incubation with diseased cells of the species;
b) obtaining, from said incubation, a collection of diseased cells essentially free from non-diseased cells, by sorting said collection of diseased cells from non-diseased cells according to parameters that distinguish between said collection of diseased cells and said non-diseased cells;
c) obtaining binding molecules from said collection of diseased cells;
d) selecting, from said obtained binding molecules, an individual binding molecule that preferentially binds to said diseased cells in comparison to binding to said non-diseased cells;
e) identifying a molecular marker which, in its disease associated form, binds to said individual binding molecule selected under step d), said disease associated molecular marker being associated with said collection of diseased cells obtainable according to step b); and
f) establishing that said disease associated molecular marker has a counterpart associated with non-diseased cells wherein said counterpart is less capable of binding said individual binding molecule. - View Dependent Claims (2, 3, 4, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 27, 29, 31, 32, 33, 34, 35, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49)
-
-
5. A process for identifying a binding molecule capable of binding a subset of diseased cells, said process comprising the steps of:
-
a) incubating cells of a species with a library of binding molecules, combined with an incubation with diseased cells of said species;
b) obtaining, from said incubation, a collection of diseased cells essentially free of non-diseased cells, by sorting said collection of diseased cells from non-diseased cells according to parameters which distinguish between said collection of diseased cells and said non-diseased cells;
c) obtaining binding molecules from said collection of diseased cells;
d) selecting, from said obtained binding molecules, an individual binding molecule capable of preferentially binding to said diseased cells as compared to binding to said non-diseased cells;
e) recovering said individual binding molecule selected in step d); and
f) establishing that said individual binding molecule preferentially binds to disease associated molecular marker, said disease associated molecular marker being associated with said diseased cells, said disease associated molecular marker further having a counterpart associated with non-diseased cells wherein said counterpart is less capable of binding said individual binding molecule. - View Dependent Claims (6, 7)
-
- 21. A binding molecule capable of specifically binding to an epitope present in a subset of CD46 proteins.
-
36. Use of an epitope expressed on a subset of CD46 expressing cells as a marker for neoplastic cells.
Specification